Lacerol

Diltiazem Hydrochloride, the active ingredient in Lacerol, is a calcium channel blocker presented as an oral tablet for systemic use. It is employed to manage high blood pressure, relieve angina pectoris, and control certain cardiac rhythm disorders in adult patients. GNH USA supplies Lacerol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacerol, a calcium channel blocker, acts on the cardiovascular system to improve blood flow and reduce cardiac workload. - Hypertension: lowers systemic arterial pressure and reduces vascular resistance. - Angina pectoris: alleviates chest pain by decreasing myocardial oxygen demand. - Stable angina: improves exercise tolerance and reduces frequency of anginal episodes. - Atrial fibrillation: helps control ventricular rate by slowing atrioventricular conduction.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate pain often occurring early in therapy. - Flushing: transient warmth and reddening of the skin. - Peripheral edema: swelling, typically of the ankles. - Dizziness: sensation of light‑headedness, especially upon standing. - Nausea: mild gastrointestinal upset. - Fatigue: generalized tiredness.

Serious or Rare Side Effects: - Bradycardia: abnormally slow heart rate requiring medical attention. - Severe hypotension: marked drop in blood pressure causing faintness. - Heart block: impaired electrical conduction through the AV node. - Hepatic injury: signs of liver dysfunction such as jaundice. - Allergic reaction: rash, itching, swelling, or anaphylaxis.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications. - Monitor blood pressure: adjust dose if target levels are not achieved. - Assess cardiac function: especially in patients with existing conduction abnormalities. - Review concomitant beta‑blocker use: combined therapy may cause excessive bradycardia. - Use caution in hepatic impairment: dose adjustments may be required. - Avoid abrupt discontinuation: taper to prevent rebound hypertension. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Diltiazem may interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase diltiazem plasma levels. - Beta‑blockers (e.g., metoprolol): may cause excessive bradycardia or AV block. - Digoxin: elevated digoxin concentrations leading to toxicity.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): reduce diltiazem effectiveness. - NSAIDs (e.g., ibuprofen): may blunt antihypertensive response. - Alcohol: can enhance hypotensive effects.